Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of subcutaneous secukinumab in polymyalgia rheumatica
2023-508077-85-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, open-label, single-arm trial of secukinumab in polymyalgia rheumatica (PMR), sponsored by Novartis. Primary endpoint: Incidence of adverse events and serious adverse events. Planned start Nov 2024; status: authorised.
02
Drugs
secukinumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2023-508077-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508077-85-00.